Translating Precision Medicine for Autism Spectrum Disorder

STALICLA is a biotech company focusing on Autism Spectrum Disorder (ASD). Using big data analytics, STALICLA is changing the paradigm in ASD drug development by bringing disease modifying and personalized medicine to patients with high unmet medical need.

Find out more about our pipeline

Autism Spectrum Disorder statistics

A highly common condition 10 million patients in USA + EU
Lack of clear characteristics 80% of cases are idiopathic
No treatment 0 treatments address core symptoms
High economic burden Cost of ASD was $268 billion in 2015 in USA

Matching the right treatment with the right patient

STALICLA is a mission-driven biotech company, with a unique patient centric vision, that is poised to become a disruptive industry challenger and future global leader in personalized treatment options for patients with Autism Spectrum Disorder (ASD). We have developed a disruptive approach, the Databased Endophenotyping Patient Identification technology. Databased Endophenotyping Patient Identification uses big data analytics, to match the right treatment with the right ASD patients.

STALICLA is headquartered in Geneva, Switzerland.

The company has established a research partnership with the Greenwood Genetic Center, a leading research center for ASD based in South Carolina, USA.

Matching the right treatment with the right patient

Databased Endophenotyping Patient Identification technology

STALICLA has taken a unique approach to bringing personalized medicine to patients with ASD. We have built an innovative algorithm platform, which identifies targeted biomarkers for specific subtypes and generates potential highly targeted repurposed drugs.

Find out more

Search for content on Stalicla...